Across TCGA pan-cancer cohorts, PFDN6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PFDN6 data layer compared with 28 for mass-spec protein and 1 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher PFDN6 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PFDN6 expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.
GBM, CCRCC, and HNSC are the cancer types where PFDN6 mass-spec protein most reproducibly stratifies survival.
mass-spec protein survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.